Surgical management and clinical prognosis of adrenocortical carcinoma

Urologia Internationalis

Volumn 88, Issue 4, 2012, Pages 400-404

  Dong, Dexin ^a   Li, Hanzhong ^a   Yan, Weigang ^a   Ji, Zhigang ^a   Mao, Quanzong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Adrenocortical carcinoma; Prognosis; Stages I IV; Surgery

Indexed keywords

ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862765928     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000336134     Document Type: Article

References (19)

1. Icard P, Chapuis Y, Andreassian B, et al: Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112: 972-979.
2. Lee JE, Berger DH, el-Naggar AK, et al: Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995;118: 1090-1098.
3. Rodgers SE, Evans DB, Lee JE, et al: Adrenocortical carcinoma. Surg Oncol Clin N Am 2006;15: 535-553.
4. Van Ditzhuijsen CI, van de Weijer R, Haak HR: Adrenocortical carcinoma. Neth J Med 2007; 65: 55-60.
5. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al: Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88: 711-736.
6. Shaikh AH, Khalid SE, Junejo NN: Adrenocortical carcinoma with endocrine syndromes. J Coll Physicians Surg Pak 2007; 17: 694-696.
7. Chouairy CJ, Abdul-Karim F, MacLennan GT: Adrenocortical carcinoma. J Urol 2008;179: 323.
8. Fulmer BR: Diagnosis and management of adrenal cortical carcinoma. Curr Urol Rep 2007;8: 77-82.
9. Assié G, Antoni G, Tissier F, et al: Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007;92: 148-154.
10. Ohwada S, Izumi M, Kawate S, et al: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol 2007;37: 108-113.
11. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B, German ACC Registry Group: Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95: 4925-4932.
12. Kendrick ML, Lloyd R, Erickson L, Farley D, Grant CS, Thompson GB, Rowland C, Young WF Jr, van Heerden JA: Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001; 136: 543-549.
13. Wängberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Odén A, Ahlman H: The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 2010; 17: 265-272.
14. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A: Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006; 30: 872-878.
15. Satter EK, Barnette DJ: Adrenocortical carcinoma with delayed cutaneous metastasis. J Cutan Pathol 2008; 35: 677-680.
16. Zardi EM, Santini D, Vincenzi B, et al: Surgical complications after resection of adrenal carcinoma. J Exp Clin Cancer Res 2006; 25: 449-451.
17. Terzolo M, Berruti A: Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2008; 15: 221-226.
18. Bertherat J, Coste J, Bertagna X: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 2007;357: 1257-1258.
19. Fareau GG, Lopez A, Stava C, et al: Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs 2008; 19: 637-644.